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Renal response to captopril reflects state of local renin system
in healthy humans
NAOMI D. L. FISHER, DEBORAH A. PRICE, W. REID LITCHFIELD, GORDON H. WILLIAMS, and
NORMAN K. HOLLENBERG
Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Renal response to captopril reflects state of local renin system and congestive heart failure. Evidence has been gathered
in healthy humans. from the realms of molecular biology and physiology,
Background. Heightened activity of the renin-angiotensin genetics and therapeutics [1–10]. Recently, these same
system has been linked to the development of both essential lines of investigation have provided insights into controlhypertension and diabetic nephropathy. Blunting of the renal
mechanisms in healthy individuals, which might explainvasoconstrictor response to Ang II, specifically when it is cor-
why some apparently normal people are at greater riskrected by angiotensin converting enzyme (ACE) inhibition, is
a feature which we have employed as a marker for activation than others of developing a disease and its complications.
of the intrarenal RAS. In this study we tested the hypothesis Polymorphisms involving candidate genes in the RAS
that variation in the renal vasodilator response to ACE inhibi- have been linked to the development of both essential
tion in healthy humans reflected the variation in angiotensin- hypertension and diabetic nephropathy [5–10]. In both
mediated renal vasoconstriction provoked by a low-salt diet.
cases there has been substantial controversy, as someMethods. We studied 20 healthy people (ages 19 to 57; 15
groups have found an association between a specific ge-males) who were in balance on a low sodium diet. Ang II was
netic polymorphism and disease and others have notinfused for 45 minutes (3 ng/kg/min), followed by 25 mg capto-
pril and a repeat Ang II infusion; PAH clearance was measured [5–10]. This is precisely the situation in which an “inter-
at the end of each interval. mediate phenotype,” namely a physiological mechanism
Results. All subjects responded to captopril with a rise in that bridges the gap between genotype and ultimate dis-
renal plasma flow (range 43 to 242, mean 118 1 12 ml/min/ ease expression, could prove most useful [10]. Hopkins1.73 m2). Individual vasodilator response to captopril was a
et al have shown a strong association between a commonstrong inverse predictor of the precaptopril vasoconstrictor
variant in the angiotensinogen (AGT) gene and bluntingresponse to Ang II (P 5 0.006, r 5 20.59). There was a stronger,
of the renal vascular response to angiotensin II (Ang II),positive correlation of the vasodilator response to captopril
and enhancement of Ang II responsiveness after captopril (r 5 not only in hypertensive patients, but in healthy normal
0.57). Plasma renin activity was significantly correlated with subjects as well [11]. Blunting of the renal vasoconstrictor
captopril response among the large responders (P 5 0.003; r 5 response to Ang II, specifically when it is corrected by
0.83), but not at all among those with little response. angiotensin converting enzyme (ACE) inhibition, is aConclusion. These results suggest substantial variation in
feature which we have employed as a marker for activa-angiotensin-mediated control of the renal circulation in healthy
tion of the intrarenal RAS [1, 12, 13].individuals on a low sodium intake. Variation in the vasodilator
response to captopril, correlated with responses to Ang II, Our overall goal in this study was to develop more
provides a measure of that control. fully this intermediate phenotype, and specifically to test
the following hypothesis: blunting of the renal vascular
response to Ang II in normal humans is associated with
The renin-angiotensin system (RAS) has been impli- a larger renal vasodilator response to ACE inhibition,
which in turn produces a greater renal vascular responsecated in the pathogenesis of several common diseases,
to a second Ang II infusion. This constellation of findingsincluding essential hypertension, diabetic nephropathy,
has been documented in hypertension and in diabetes
mellitus [10, 13]. However, it is unclear whether or not
Key words: angiotensin II, renal circulation, sodium, angiotensin con- these relationships are seen only in pathologic states or
verting enzyme inhibition, angiotensinogen, hypertension, vasocon- are, in fact, an exaggeration of normal physiology.striction.
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Table 1. Response to captopril
Basal RPF First Peak captopril Enhancement of
before captopril AngII response response AngII response
(A) (B2A) (C2A) (D2C)2 (B2A)
BMI
Subject Age Gender kg/m2 ml /min /1.73 m2
1 23 F 21.7 701 2130 43 12
2a 49 M 25.5 470 270 44 35
3 41 M 23.6 505 271 51 60
4a 39 M 23.6 912 296 80 149
5a 24 M 25.4 538 2103 83 224
6a 46 M 24.2 645 2109 83 55
7 27 F 28.5 586 2107 90 73
8 22 F 20.5 627 2125 94 38
9a 33 M 25.2 590 274 98 76
10 24 M 19.9 633 295 100 58
11a 42 M 21.1 595 297 117 107
12 24 F 23.5 636 288 121 78
13 23 M 20.2 521 253 124 65
14 57 M 30.8 566 263 124 114
15a 36 M 25.7 556 287 148 46
16 27 F 22.2 584 2100 162 98
17 28 M 21.6 583 294 169 97
18 19 M 22.1 549 257 190 103
19 19 M 21.8 519 236 198 88
20a 20 M 21.7 713 238 242 140
Mean 31.2 23.4 601 285 118 73
sd 11.1 2.8 95.8 26.3 53.3 41.5
se 2.5 0.6 21.4 5.9 11.9 9.3
A,B,C,D, see Statistical Considerations (under Methods section) for definitions.
a Pre-captopril Ang II infusion performed on a separate day
cardiovascular, renal and endocrine disease, and were curve [14]. To assess the effect of captopril on the tissue
sensitivity to Ang II, the Ang II infusion was repeated 90within 20% of ideal body weight. After an outpatient
evaluation including physical examination and screening minutes after captopril was given. In those eight subjects
who spent at least five days as inpatients, the first Anglaboratory studies, subjects were admitted to a metabolic
ward, the General Clinical Research Center of The Brig- II infusion was performed on a day separate from the
captopril-Ang II protocol, but always during the sameham and Women’s Hospital. The protocol was approved
by the Human Subjects Committee of the institution, and inpatient stay, and within two to four days. These pa-
tients are noted in Table 1. Captopril-response data onwritten informed consent was obtained from each subject.
All subjects were placed on low-salt, constant isoca- these patients have been previously reported [15].
Blood pressure during each infusion was recorded byloric diets throughout the entire hospitalization, with
10 mmol daily sodium intake. Subjects began their low an automatic recording device (Dinamap) at five minute
intervals during the treatments and at two minute inter-sodium diet as outpatients. Daily dietary potassium (100
mmol) and fluid intake (2500 ml) were constant. Eight vals during the Ang II infusions. If blood pressure fell
in these normal subjects, it was slight and transient, andsubjects were admitted five days before the study, and
achieved sodium balance as inpatients. In the other 12, not captured with our blood pressure measurements.
Changes in renal vascular resistance therefore parallelthe inpatient element of the protocol was only two days.
Twenty-four hour urine samples were collected daily and changes in RPF. Blood samples were drawn for measure-
analyzed for sodium, potassium, and creatinine. When ment of PAH and PRA at baseline, and at the end of
sodium excretion matched sodium intake (usually on each study period.
days 5 to 7) the first study was initiated.
Renal clearance studiesEach study day began with a 60-minute baseline infu-
sion of para-aminohippurate (PAH), which continued Para-aminohippurate (PAH; Merck Sharp and Dohme,
West Point, PA, USA) concentrations were assessed bythroughout the protocol. Ang II (Hypertensin Ciba) was
infused for 45 minutes at 3 ng/kg/min. This dose was used an autoanalyzer technique after achieving metabolic bal-
ance [1]. An intravenous catheter was placed in each ofbecause it has been found to affect renal plasma flow
(RPF) with minimal pressor effects. Immediately follow- the subject’s arms, one for infusion and the other for
blood sampling. The subjects were supine, and had beening, captopril was delivered as a 25 mg tablet, known to
be at the top of the renal vasodilator dose–response fasting for at least 8 hours. A control blood sample was
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Table 2. Normal renal plasma flow (RPF) response to captopril (X):
Univariate correlation
y r P
RPF response to AngII 0.59 0.006
Enhancement of RPF response
to AngII after captopril 0.57 0.009
Age 20.43 0.06
Basal plasma renin activity 0.41 0.07
Not significant: BMI, UNa, Basal RPF.
tervals before Ang II and before captopril. RPF at the
conclusion of the first Ang II infusion, at time 45 minutes,
is hereafter termed [B]. The peak RPF achieved follow-
ing captopril administration is represented by [C], while
[D] represents the RPF immediately following the sec-
ond Ang II infusion. Ang II responsiveness was deter-
mined by means of clearance measurements at the start
and end of each Ang II infusion (precaptopril Ang II
response 5 [B – A]; postcaptopril Ang II response 5Fig. 1. Correlation between renal vasodilator response to captopril 25
mg and renal vasoconstrictor response to a precaptopril infusion of angio- [D 2 C]). “Enhancement” of Ang II responsiveness was
tensin II (Ang II; 3 ng/kg/min for 45 min). Those subjects with the largest
calculated by subtracting the precaptopril vasoconstric-increase in renal plasma flow (RPF) following captopril [C 2 A] had
the smallest fall in RPF following Ang II [B 2 A]. Definitions of the tor response to Ang II from the response following a
variables are in the Methods section (r 5 0.59; P 5 0.006). dose of captopril ([D 2 C] 2 [B 2 A]); this measure was
larger in 19 of 20 subjects). Analyses of these expressions
enabled us to test the hypothesis that blunting of the
renal vascular response to Ang II in normal humansobtained and then loading doses of PAH (8 mg/kg) were
[B 2 A] is associated with a larger renal vasodilatorgiven, followed immediately by a constant infusion at a
response to ACE inhibition [C 2 A], which in turn pro-rate of 12 mg/min with an IMED pump (IMED Corp.,
duces a greater renal vascular response to a second Ang II
San Diego, CA, USA). This rate achieves plasma PAH
infusion [D 2 C]. Correlation analyses were performed
concentration in the middle of the range in which tubular
between the major variable, the renal vascular response
secretion dominates excretion. At this plasma level of
to captopril, and other demographic and physiologic
PAH, clearance is independent of plasma concentration
variables. Because a categorical analysis based on geno-
and, when corrected for individual body surface area, typic considerations provided part of the rationale for
represents about 90% of RPF. Plasma samples reflecting this study, we also undertook analysis by category, to
the control clearances were obtained 60 minutes after ascertain whether a subset of “responders” or “nonre-
the start of the PAH infusion when a steady state had sponders” existed. Comparisons between groups were
been achieved, and at 45-minute intervals thereafter. performed via t-tests. Group means have been presented
with the standard error of the mean as the index ofLaboratory procedures
dispersion. The alpha level for significance was ,0.05.
Blood samples were collected on ice, spun immedi-
ately, and the plasma frozen until the time of assay. Urine
RESULTSsodium levels were measured by flame photometry, with
lithium as an internal standard. Serum PAH was mea- There was a range of basal RPF prior to Ang II and
sured by an autoanalyzer technique [1]. PRA was as- prior to captopril (470 to 912 ml/min/1.73 m2; A; Table 1).
sayed by radioimmunoassay techniques that have been All of the subjects responded to captopril with an in-
described in detail [16]. crease in RPF which averaged 118 6 12 ml/min/1.73 m2
[C 2 A]. As anticipated, there was a wide range of
Statistical considerations responsiveness to captopril among the subjects (43 to
Renal plasma flow values at specific timepoints through- 242 ml/min/1.73 m2; Table 1). Individual vasodilator re-
out the protocol have been designated with letter names sponse to captopril [C 2 A] was a strong inverse pre-
to facilitate clear and consistent presentation. Basal RPF dictor of the first, precaptopril vasoconstrictor response
[A] was defined as the mean of three basal PAH clear- to Ang II [B 2 A]: those subjects with the largest response
to captopril had the smallest to Ang II (P 5 0.006; r 5ances, calculated from samples drawn at five minute in-
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As anticipated, the corresponding responses to Ang II
[B 2 A] and mean enhancement of Ang II response
([D 2 C] 2 [B 2 A]) also differed significantly (Fig. 3).
Among the total group of subjects there was only a
trend toward a significant correlation between the capto-
pril response [C 2 A] and our measure of activity of the
circulating RAS, namely PRA (r 5 0.41; P 5 0.07; Fig. 4).
Among the large responders, however, the significance
was striking (r 5 0.83; P 5 0.003; Fig. 5). The intercept
in the relationship between basal PRA and the RPF
response to captopril was about 100 ml/min/1.73 m2, and
the RPF response exceeded 200 ml/min/1.73 m2 in those
with the highest basal PRA. Conversely, in those subjects
with small renal vasodilator responses to captopril, over
a wide and overlapping range of basal PRA, the renal
vasodilator response showed no tendency to increase
with increasing basal PRA.
DISCUSSION
The roots of this study lay, in part, in our earlier obser-Fig. 2. Correlation between renal vasodilator response to captopril and
vation of a large variability in the renal vascular respon-enhancement of renal vasoconstrictor response to a second infusion of
Ang II following a dose of captopril. “Enhancement” of response was siveness to agents that block the RAS [15]. Previously,
calculated by subtracting the precaptopril vasoconstrictor response to the wide range of individual renal vasodilator responsesAng II [B 2 A] from the response following captopril [D 2 C] (r 5
to captopril was considered to result from noise inherent0.57; P 5 0.009).
in the PAH clearance measurement. Instead, our hy-
pothesis suggested that the range portrays real biological
variation. The correlation unveiled in this study between
20.59; Fig. 1). None of the demographic variables was a large renal vasodilator response to captopril, small
found to correlate significantly with captopril response, basal vasoconstrictor response to Ang II, and enhance-
but age was close (r 5 20.43; P 5 0.06; Table 2). In ment of the Ang II response following captopril adminis-
this population with a relatively narrow age range, this tration confirms our hypothesis.
relationship did not depend on the known correlation Angiotensin-converting enzyme (ACE) has a wide
between age and basal RPF. There was no correlation range of substrates, including bradykinin. ACE inhibition
between captopril response and body mass index, urinary can result in bradykinin accumulation, which can then
sodium excretion, or basal RPF. lead to vasodilation through several pathways, including
Following captopril, enhancement of the vasoconstric- vasodilator prostaglandin release and activation of nitric
tor response to Ang II beyond the precaptopril Ang II- oxide synthesis [17, 18]. Thus, a vasodilator response to
induced vasoconstriction was found to correlate strongly captopril could reflect either a reduction in Ang II forma-
with the vasodilator response to captopril (P 5 0.009; r 5 tion or increased vasodilator production. For that reason,
0.57; Fig. 2). This positive correlation meant that those we have employed responsiveness to Ang II as a decisive
subjects with the highest captopril-induced renal vasodi- element in our studies. Because bradykinin, vasodilator
lator response [C 2 A] had the largest increase in the prostaglandins, and nitric oxide all blunt renal vascular
renal vasoconstrictor response to Ang II following capto- responses to Ang II, whereas a reduction in Ang II for-
pril ([D 2 C] 2 [B 2 A]). mation enhances the same response, the influence of the
When the subjects were divided into two equal groups ACE inhibitor on responsiveness to Ang II provides
on the basis of their captopril response [C 2 A], there insight into the responsible vasodilator mechanism.
emerged clear differences between those with large re- Thus, the enhancement of Ang II-induced vasocon-
sponses and those with small (means 77 6 7 vs. 160 6 13 striction following ACE inhibition in this study suggests
ml/min/1.73 m2). There was no discernable demographic that captopril acted primarily by decreasing Ang II con-
difference between the two groups, including urinary centration and not by increasing bradykinin or prosta-
sodium (7 6 2 in the low responders vs. 13 6 2 in the high). glandins or nitric oxide. These results are in accord with
The distribution of responses to captopril appeared to be animal studies, which indicate that the renal vasodilator
continuous; the high responders included all those with response to captopril is dominated by a reduction in Ang II
formation [19, 20].captopril responses greater than 100 ml/min/1.73 m2.
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Fig. 3. Subjects were divided into two equal
groups based upon the magnitude of their re-
nal perfusion flow (RPF) response to capto-
pril. (A) Inverse relationship between the va-
sodilator response to captopril [C 2 A] and
precaptopril vasoconstrictor response to angi-
otension (Ang II; [B 2 A]; P 5 0.02). (B)
Positive relationship between captopril re-
sponse [C 2 A] and enhancement of Ang II
response following captopril ([D 2 C] – [B 2
A]; P 5 0.009). Subjects with large captopril
responses had small precaptopril responses to
Ang II. Following captopril, however, these
same subjects had a greater response to Ang II
(Wilcoxin rank sum test analysis).
gest a substantial variation in the contribution of Ang II
to maintenance of renal vascular tone, a range of renin
system activation that is not necessarily reflected in
plasma renin activity. Multiple lines of evidence sug-
gesting an independent intrarenal RAS are corroborated
by this study [23].
If, indeed, a large response to captopril reflects the
contribution of Ang II to maintenance of renal vascular
tone, our hypothesis would predict that other means for
blocking the RAS would also induce an enhanced renal
vasodilator response. We have performed such a validat-
ing study, in a comparison of renal vascular responses
to captopril and to the specific renin inhibitor enalkiren,
in healthy young subjects on the same diet [15]. We
found not only remarkable concordance between the
renal vasodilator response to captopril and to enalkiren
(r 5 0.88), but also remarkable concordance in the en-
hancement of responsiveness to Ang II induced by these
two agents that block the RAS at different levels. Be-
Fig. 4. Correlation between basal plasma renin activity and renal vaso- cause that observation was based not on a prior hypothe-
dilator response to captopril 25 mg [C 2 A] among the 20 subjects.
sis, but rather on inspection of the data, we drew conser-There was a trend toward significance (r 5 0.41; P 5 0.07).
vative conclusions until supporting evidence could be
obtained. This study provides unambiguous confirmation
that there is substantial variation in angiotensin-medi-
Much of the evidence for heightened activity of the ated control of the renal circulation in healthy individu-
RAS in disease has emerged from studies involving ACE als, in whom other elements involved in the control of
inhibition. Correction of a blunted renal vasoconstrictor renin release or intrarenal Ang II generation have been
response to Ang II by ACE inhibition is a fundamental controlled. Potential causes for this variation include the
feature of the syndrome of nonmodulation, marked by genes governing the RAS; polymorphisms of the AGT
dysregulated Ang II responsiveness [10, 12]. In therapeu- gene have been shown to influence control of renal vas-
tic trials, the efficacy of ACE inhibition in reducing the cular tone, not only in patients with essential hyperten-
progression of nephropathy in both type I and type II sion, but also in normotensive subjects [11].
diabetes has been replicated multiple times [2, 21]. More The range of individual renal vascular hemodynamic
recently, ACE inhibition has been shown to correct ab- responses to captopril and the internally consistent re-
normally elevated sodium-lithium countertransport [22]. sponses to Ang II, coupled with data relating renal vascu-
The subjects in this study were all healthy, studied lar responsiveness to AGT genotype, furthered our sus-
in the recumbent position and on a low-sodium, high- picion of underlying genetic control. A strong family
potassium intake, with carbohydrate and protein intake history of hypertension in nonmodulation, taken together
controlled. Thus, many of the determinants of renin re- with concordance of Ang II responsiveness within sibling
pairs and a frequency distribution suggestive of an inter-lease were controlled. Despite this control, our data sug-
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Fig. 5. Correlation between basal PRA and
captopril-induced renal vasodilator response,
with subjects divided according to vasodilator
response to captopril. Note the overlapping
range of PRA between the two groups. (A)
Captopril response [C 2 A] among the large
responders was amplified by a high renin (r 5
0.83; P 5 0.003). (B) Captopril response among
those with a small response ignores renin (P 5
0.02).
mediate phenotype, have all strengthened the supposi- correlate with these findings. Hopkins et al found no
genotypic effect on plasma AGT levels in a much largertion that genetic forces underlay the development of this
syndrome [24]. The decision to examine this database sample size of 120 [11]. In an even larger study of hyper-
tensive siblings, higher plasma AGT concentrations werefor patient subsets was governed by these considerations,
as genetic polymorphisms imply categorical responses. seen among carriers of the abnormal T235 allele [5], but
the range of AGT concentration in plasma (1300 to 1600Inspection of the renal vasodilator response to captopril
showed no inflection point or hint of bimodality that ng/ml) is narrow in contrast with range of response. Al-
ternatively, the increase in AGT underlying heightenedwould have provided a cut point. For that reason, and
because of the expectation of categorical results, we di- captopril responsiveness might well lie at the tissue level.
Intrarenal AGT mRNA has been localized predomi-vided the subjects at the median, following which analysis
led to revealing relationships. nantly in the proximal renal tubule [26].
In the pathogenesis of complex disease states, suchPlasma renin activity showed only a weak correlation
with the renal vasodilator response to captopril. Examin- as essential hypertension and diabetic nephropathy, in
which major genes and environmental factors interact,ing this same relationship after dividing the subjects re-
vealed a startling dichotomy. The 10 subjects in whom the concept of the “intermediate phenotype” has become
crucial [10]. In the case of renal control mechanisms,the response was blunted showed no correlation between
rise in PRA and vasodilator response to captopril. In where angiotensin plays a major role, the constellation
of findings in a subset of healthy subjects revealed inthe subjects in whom the renal vasodilator response was
prominent, on the other hand—over an overlapping this study—blunting of the renal vascular response to
Ang II and enhanced response to captopril, followed byrange of PRA—there was a striking correlation between
PRA rise and renal vasodilator response (r 5 0.83). The correction of the blunting of the renal vascular response
to Ang II—have been useful for exploring mechanismsintercept of that relationship, at a PRA rise of 0, reflected
a rise in RPF of about 100 ml/min/1.73 m2—the dividing of hypertension and diabetes [10, 13]. In general, those
studies have been most informative when performed inline between the large and small response—and a value
above any of the responses in the lower group. This patients on a high salt diet, and the informative index
for dividing the patient subsets has involved the renalvalue is also the average low salt ACE inhibitor response
generated from previous studies [25]. With increasing vascular response to Ang II before ACE inhibition. In
this study, performed with patients on a low salt diet, theactivation of the renin system, reflected in a rise in PRA,
the renal vasodilator response rose significantly. One informative marker proved to be the renal vasodilator
response to captopril. These observations suggest thatexplanation for this correlation between PRA and renal
vascular responsiveness among large responders is spillo- the renal vasodilator response to captopril, or to other
agents that block the RAS, can serve as an informativever from a heightened intrarenal system into the circula-
tion. Alternatively, these observations are compatible intermediate phenotype.
Greater vasodilation with captopril, associated with awith activation of the intrarenal renin system due to
some factor other than renin release. One speculative low basal vasoconstrictor response to Ang II but a large
enhancement of vasoconstriction following the ACE in-possibility involves AGT formation.
While we have not yet measured AGT in this study, hibitor, strongly suggests more active renal vasoconstric-
tion due to Ang II in these subjects. While future investi-it would not be surprising if serum concentration did not
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and their impact on therapeutic interventions. Kidney Intgation will surely involve molecular genetic studies in
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